Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse.

ABSTRACT: Therapeutic cancer vaccines aim to induce an effective immune response against cancer, and the effectiveness of these vaccines is influenced by the choice of immunogen, vaccine type, and immunization strategy. Although treatment with cancer vaccines can improve tumor burden and survival, in most animal studies, it is challenging to achieve a complete response against tumor growth and recurrence, without the use of other therapies in combination. Here, we present a novel approach where dual antigens (survivin and MUC1) are co-targeted using three DNA vaccines, followed by a single booster of a recombinant modified vaccinia Ankara (MVA) vaccine. This heterologous vaccination strategy induced higher levels of interferon (IFN)-γ-secretion and stronger antigen-specific T-cell responses than tho

SUBMITTER: Guo Q 

PROVIDER: S-EPMC7657584 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature